




INVESTOR IN PROPERTIES

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

28 August 2001



Patents Form 1/77

Patents Act 1977
(Rule 16)

THE PATENT OFFICE

- 6 APR 2001

NEWPORT



06APR01 E620085-1 D02934
P01/7700 0.00-0108654.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

100203-GB-2

2. Patent application number

(The Patent Office will fill in this part)

0108654.5

06 APR 2001

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
S-151 85
Sodertalje
SWEDEN

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

SWEDEN

7822448003

4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (if you have one)

A Giles

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Ltd
Global Intellectual Property-Patents
PO BOX 272
Mereside
Alderley Park
Macclesfield
Cheshire, SK10 4GR, UK

Patents ADP number (if you know it)

6988463003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	21
Claim(s)	5
Abstract	1
Drawing(s)	

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11 pages of sequence listing. (x2)

11.

I/We request the grant of a patent on the basis of this application.

Authorised signatory

Signature

Lynda M Slack

Date

05 04 2001

12. Name and daytime telephone number of person to contact in the United Kingdom

01615 516173 AstraZeneca - Lynda Slack

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

CHEMICAL COMPOUNDS

This invention relates to polymorphisms in the human P2X₇ gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the P2X₇ gene, and to the use of P2X₇ polymorphism in treatment of diseases with P2X₇ drugs.

The P2X₇ receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflammatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B). Activation of the P2X₇ receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin-1 β (IL-1 β) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and L-selectin shedding (lymphocytes). P2X₇ receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells) and hepatocytes. Compounds acting at the P2X₇ receptor are therefore indicated as pharmaceuticals for use in the treatment of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), hyperresponsiveness of the airway, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke and varicose veins. For further background, the reader is referred to the following articles: North and Barnard in Current Opinion in Neurobiology 1997, 7, 346-357; Rassendren, JBC, 1997, 273, 5482-6; and Buell, Receptors and Channels, 1998, 5, 347-354. The terms P2X₇, P2X₇ receptor and P2RX7 are used interchangeably herein.

All positions herein of polymorphisms in the 5' UTR region of the P2X₇ polynucleotide relate to the position in SEQ ID NO 1 unless stated otherwise or apparent from the context.

All positions herein of polymorphisms in the exon regions of the P2X₇ polynucleotide relate to the position in SEQ ID NO 2 unless stated otherwise or apparent from the context.

All positions herein of polymorphisms in the intron regions of the P2X₇ polynucleotide relate to the position in SEQ ID NO 3 unless stated otherwise or apparent from the context.

All positions herein of polymorphisms in the P2X₇ polypeptide relate to the position in SEQ ID NO 4 unless stated otherwise or apparent from the context.

One approach is to use knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed

- 5 "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), *Clinical Chemistry*, 43, 254; Marshall (1997), *Nature*
10 *Biotechnology*, 15, 1249; International Patent Application WO 97/40462, *Spectra Biomedical*; and Schafer *et al.* (1998), *Nature Biotechnology*, 16, 33.

Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

- 15 Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

- 20 The present invention is based on the discovery of polymorphisms in P2X₇. In particular, we have found thirty polymorphisms in the coding sequence of the P2X₇ gene, 12 of which lead to changes in the sequence of expressed protein.

- According to one aspect of the present invention there is provided a method for the diagnosis of a polymorphism in P2X₇ in a human, which method comprises determining the
25 sequence of the human at at least one polymorphic position and determining the status of the human by reference to polymorphism in P2X₇. Preferred polymorphic positions are one or more of the following positions:

positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1;

- 30 positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and

positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3;

positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4.

- 5 The term human includes both a human having or suspected of having a P2X₇ mediated disease and an asymptomatic human who may be tested for predisposition or susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

- The term polymorphism includes single nucleotide substitution, nucleotide insertion
10 and nucleotide deletion which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene and corresponding alterations in expressed protein.

- In one embodiment of the invention preferably the method for diagnosis described herein is one in which the polymorphism in the in the 5'UTR region of the P2X₇ gene as
15 defined by the position in SEQ ID NO: 1 is any one of the following:
at position 936 is presence of C and/or A; at position 1012 is presence of T and/or C;
at position 1147 is presence of A and/or G; at position 1343 is presence of G and/or A; and
at position 1476 is presence of A and/or G.

- In one embodiment of the invention preferably the method for diagnosis described
20 herein is one in which the polymorphism in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2 is any one of the following:
at position 253 is presence of T and/or C; at position 488 is presence of G and/or A;
at position 489 is presence of C and/or T; at position 760 is presence of T and/or G;
at position 835 is presence of G and/or A; at position 853 is presence of G and/or A;
25 at position 1068 is presence of G and/or A; at position 1096 is presence of C and/or G;
at position 1315 is presence of C and/or G; at position 1324 is presence of C and/or T;
at position 1405 is presence of A and/or G; at position 1448 is presence of C and/or T;
at position 1494 is presence of A and/or G; at position 1513 is presence of A and/or C;
at position 1628 is presence of G and/or T; and at position 1772 is presence of G and/or A.

- 30 In one embodiment of the invention preferably the method for diagnosis described herein is one in which the polymorphism in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3. is any one of the following:

- at position 4780 is presence of C and/or T; at position 4845 is presence of C and/or T;
at position 4849 is presence of A and/or C; at position 5021 is presence of T and/or C;
at position 5554 is presence of 3 and/or 4 repeats of GTTT (wherein position 5554 refers to
the position of the G in the first unit repeat);
- 5 at position 5579 is presence of G and/or C; at position 5535 is presence of A and/or T;
at position 5845 is presence of C and/or T; and at position 6911 is presence of T and/or C.

In one embodiment of the invention preferably the method for diagnosis described
herein is one in which the polymorphism in the P2X₇ protein as defined by the position in
SEQ ID NO: 4. is any one of the following: val76ala, his155tyr, val245gly, arg270his,
10 arg276his, ala348tyr, thr357ser, pro430arg, ala433val, gln460arg, ser490gly and glu496ala.

The method for diagnosis is preferably one in which the sequence is determined by a
method selected from amplification refractory mutation system, restriction fragment length
polymorphism and primer extension.

The status of the individual may be determined by reference to allelic variation at any
15 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30 or more positions.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar
lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be
appreciated that the test sample may equally be a nucleic acid sequence corresponding to the
20 sequence in the test sample, that is to say that all or a part of the region in the sample nucleic
acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of
allelic variation.

It will be apparent to the person skilled in the art that there are a large number of
analytical procedures which may be used to detect the presence or absence of variant
25 nucleotides at one or more polymorphic positions of the invention. In general, the detection
of allelic variation requires a mutation discrimination technique, optionally an amplification
reaction and optionally a signal generation system. Table 1 lists a number of mutation
detection techniques, some based on the PCR. These may be used in combination with a
number of signal generation systems, a selection of which is listed in Table 2. Further
30 amplification techniques are listed in Table 3. Many current methods for the detection of
allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in
standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. •

Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
ELISA	Enzyme Linked ImmunoSorbent Assay
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis

5 Table 1 - Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

* Note: not useful for detection of promoter polymorphisms.

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips).

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)

Extension Based: ARMST™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

10 Restriction Enzyme Based: RFLP, Restriction site generating PCR

Ligation Based: OLA

Other: Invader assay

Table 2 - Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom

15 Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 - Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

20 Table 4- Protein variation detection methods

Immunoassay

Immunohistology

Peptide sequencing

Preferred mutation detection techniques include ARMST™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques.

Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2nd edition, C P Price & D J Newman, 1997, published by Stockton Press in USA & Canada and by Macmillan Reference in the United Kingdom.

30 Particularly preferred methods include ARMST™ and RFLP based methods. ARMST™ is an especially preferred method.

In a further aspect, the diagnostic methods of the invention are used to assess the pharmacogenetics of a drug acting at P2X₇.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

- 5 Individuals who carry particular allelic variants of the P2X₇ gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to
10 predict the clinical response to such agents and to determine therapeutic dose.

In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by P2X₇. This may be particularly relevant in the development of hyperlipoproteinemia and cardiovascular disease and the present invention may be used to recognise individuals who are particularly at
15 risk from developing these conditions.

In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the P2X₇ gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design
20 of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

- 25 According to another aspect of the present invention there is provided a human P2X₇ gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at
30 least 30 bases.

According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 bases of the human P2X₇ gene and comprising a polymorphism selected from any one of the following:

Region	Polymorphism SEQ ID NO: 1
5' UTR	936 C→A
	1012 T→C
	1147 A→G
	1343 G→A
	1476 A→G

Region	Polymorphism SEQ ID NO: 2
exon 2	253 T→C
exon 5	488 G→A
	489 C→T
exon 7	760 T→G
exon 8	835 G→A
	853 G→A
exon 11	1068 G→A
	1096 C→G
exon 12	1315 C→G
exon 13	1324 C→T
	1405 A→G
	1448 C→T
	1494 A→G
	1513 A→C
	1628 G→T
	1772 G→A

5

Region	Polymorphism SEQ ID NO: 3
intron E	4780 C→T
	4845 C→T
	4849 A→C
intron F	5021 T→C
	5554 (GTTT) _{n=3,4}

	5579 G→C
	5535 A→T
intron G	5845 C→T
	6911 T→C

According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 bases of the human P2X₇ gene and comprising an allelic variant selected from any one of the following:

Region	Variant
	SEQ ID NO: 1
5'UTR	936 A
	1012 C
	1147 G
	1343 A
	1476 G

5

Region	Variant
	SEQ ID NO: 2
exon 2	253 C
exon 5	488 A
	489 T
exon 7	760 G
exon 8	835 A
	853 A
exon 11	1068 A
	1096 G
exon 12	1315 G
exon 13	1324 T
	1405 G
	1448 T
	1494 G
	1513 C
	1628 T
	1772 A

Region	Variant
	SEQ ID NO: 3
intron E	4780 T
	4845 T

	4849 C
intron F	5021 C
	5554 (GTTT) _n , n=4
	5579 C
	5535 T
intron G	5845 T
	6911 C

According to another aspect of the present invention there is provided a human P2X₇ gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one polymorphism.

- 5 Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

- According to another aspect of the present invention there is provided an allele
10 specific primer capable of detecting a P2X₇ gene polymorphism, preferably at one or more of the positions as defined herein.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as
15 used for ARMSTTM assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4,
20 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology
25 Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a P2X₇ gene polymorphism, preferably at one or more of the positions defined herein.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more
5 preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the
10 corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

According to another aspect of the present invention there is provided an allele
15 specific primer or an allele specific oligonucleotide probe capable of detecting a P2X₇ gene polymorphism at one of the positions defined herein.

According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

20 The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

In another aspect of the invention, the polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of
25 relatively high frequency. The P2X₇ gene is on chromosome 12q24 (Buell et al, Receptors and Channels, 1998, 5,347-354). Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random, there may be as many as 2ⁿ haplotypes, where 2 is
30 the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest.

The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis.

According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug acting at P2X₇ in which the method comprises:

- 20 i) diagnosis of a polymorphism in P2X₇ in the human, which diagnosis preferably comprises determining the sequence at one or more of the following positions: positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1; positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 25 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3; and positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;
- 30 and determining the status of the human by reference to polymorphism in P2X₇; and

- ii) administering an effective amount of the drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which drug or drugs to administer and/or in deciding on the effective amount of the drug or drugs. The term "drug acting at P2X₇" means that drug
5 binding with P2X₇ in humans is an important part of a drug exerting its pharmaceutical effect in man.

According to another aspect of the present invention there is provided use of a drug acting at P2X₇ in preparation of a medicament for treating a disease in a human diagnosed as having a polymorphism therein, preferably at one or more of the positions defined herein.

- 10 According to another aspect of the present invention there is provided a pharmaceutical pack comprising P2X₇ drug and instructions for administration of the drug to humans diagnostically tested for a polymorphism therein, preferably at one or more of the positions defined herein.

According to another aspect of the present invention there is provided an allelic variant
15 of human P2X₇ polypeptide comprising at least one of the following:

- a alanine at position 76 of SEQ ID NO 4;
 - a tyrosine at position 155 of SEQ ID NO 4;
 - a glycine at position 245 of SEQ ID NO 4;
 - a histidine at position 270 of SEQ ID NO 4;
 - 20 a histidine at position 276 of SEQ ID NO 4;
 - a tyrosine at position 348 of SEQ ID NO 4;
 - a serine at position 357 of SEQ ID NO 4;
 - a arginine at position 430 of SEQ ID NO 4;
 - a valine at position 433 of SEQ ID NO 4;
 - 25 a arginine at position 460 of SEQ ID NO 4;
 - a glycine at position 490 of SEQ ID NO 4; and
 - a glutamic acid at position 496 of SEQ ID NO 4;
- or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic variant.

- 30 Fragments of polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids.

According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human P2X₇ polypeptide as described herein.

Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example F(ab')₂, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of P2X₇ with a K_d of greater than or equal to about 10⁷ M⁻¹. Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660 (1949).

10 Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster
15 immunizations, small samples of serum are collected and tested for reactivity to antigen. Examples of various assays useful for such determination include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays
20 (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

25 The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Altling-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes
30 a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

According to another aspect of the invention there is provided a diagnostic kit
5 comprising an antibody of the invention.

According to another aspect of the present invention there is provided a polynucleotide comprising any one of the following twenty six P2X, haplotypes:

	1012	489	5579	835	853	1068	1096	1405	1513
	SEQ ID	SEQ ID	SEQ	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	1	2	ID 3	2	2	2	2	2	2
1	T	T	C	G	G	A	G	A	A
2	C	C	G	G	G	G	C	A	A
3	C	C	C	A	G	G	C	A	C
4	C	T	G	G	G	A	C	G	A
5	C	C	G	G	G	A	G	A	A
6	C	C	C	A	G	G	C	A	A
7	T	T	G	G	G	A	C	G	A
8	C	T	C	G	G	G	C	A	A
9	C	C	C	G	G	A	C	A	A
10	C	T	G	G	G	G	C	A	C
11	T	C	G	G	G	A	C	A	A
12	C	T	C	G	G	G	C	A	C
13	T	C	C	G	G	A	C	A	A
14	T	C	C	G	G	G	C	A	C
15	C	T	C	G	G	A	C	A	A
16	T	T	C	G	G	A	C	G	A
17	C	C	G	G	G	A	C	G	A
18	T	C	G	A	A	G	C	A	A
19	C	C	C	G	G	G	G	A	A
20	T	C	C	G	G	G	G	A	A
21	C	T	C	A	G	G	C	A	A
22	C	C	C	G	G	G	C	A	C
23	C	T	G	G	A	A	G	G	A
24	T	T	G	G	G	A	G	G	A
25	C	T	C	G	G	G	G	A	A
26	C	C	C	G	G	G	C	A	A

According to another aspect of the present invention there is provided a human P2X₇ polypeptide comprising one of the following eighteen combinations of allelic variant determined amino acids based on positions identified in SEQ ID NO: 4:

5

	155	270	276	348	357	460	496
1	Y	R	R	Y	S	Q	E
2	Y	R	R	Y	T	R	E
3	Y	R	R	Y	T	Q	E
4	Y	R	R	Y	S	R	E
5	Y	R	R	A	T	Q	A
6	Y	R	R	A	T	Q	E
7	Y	R	R	A	S	Q	E
8	Y	R	H	Y	S	R	E
9	Y	H	R	A	T	Q	E
10	H	R	R	Y	T	Q	E
11	H	R	R	Y	T	R	E
12	H	R	R	A	T	Q	A
13	H	R	R	A	S	Q	E
14	H	R	R	A	T	Q	E
15	H	R	R	Y	S	Q	E
16	H	H	R	A	T	Q	A
17	H	H	R	A	T	Q	E
18	H	H	H	A	T	Q	E

According to another aspect of the present invention there is provided a polynucleotide which encodes any human P2X₇ polypeptide combination of allelic variants defined herein.

According to another aspect of the present invention there is provided a method for the diagnosis of asthma or a predisposition thereto in a human, which method comprises

- 10 determining the sequence of the human at one or more of the following positions:
 position 1513 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and
 position 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;
 wherein presence of A at position 1513 or Glu at position 496 is diagnostic of asthma or a
 15 predisposition thereto.

The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius.

In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

- 5 General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis

- 10 (2.1.2).

Example 1

Identification of Polymorphisms

1. Methods

DNA Preparation

- 15 DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2nd Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then
- 20 phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

Template Preparation

- Templates were prepared by PCR using the oligonucleotide primers and annealing temperatures set out below. The extension temperature was 72° and denaturation temperature
- 25 94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR. Where described below, the primary fragment was diluted 1/100 and two microlitres were used as template for amplification of secondary fragments. PCR was performed in two stages (primary fragment then secondary fragment) to ensure specific amplification of the desired target sequence.

- 30 **Polymorphisms in P2X₇**

Region	Size	Polymorphism	protein change	frequency

5'UTR		936 C→A 1012 T→C 1147 A→G 1343 G→A 1476 A→G		3/56 42/56 3/56 2/52 35/52
exon 1	146bp			
intron A	21.7kb			
exon 2	168bp	253 T→C	val76ala	2/54
intron B	1.1kb			
exon 3	68bp			
intron C	4.7kb			
exon 4	73bp			
intron D	1.5kb			
exon 5	95bp	488 G→A 489 C→T	silent his155tyr	2/54 17/38
intron E	2.8kb	4780 C→T 4845 C→T 4849 A→C		39/52 39/52 28/36
exon 6	80bp			
intron F	617bp	5021 T→C 5554 (GTTT) _{n=3,4} 5579 G→C 5535 A→T		1/34 n=3, 14/40 26/40 1/44
exon 7	129bp	760 T→G	val245gly	1/40
intron G	1.3kb	5845 C→T 6911 T→C		2/40 33/50
exon 8	136bp	835 G→A 853 G→A	arg270his arg276his	16/52 1/54
intron H				
exon 9	91bp			
intron I	1.7kb			
exon 10	64bp			
intron J	84bp			
exon 11	149bp	1068 G→A 1096 C→G	ala348tyr thr357ser	18/62 5/66
intron K				
exon 12	101bp	1315 C→G	pro430arg, splice site	4/66

intron L	3.8kb			
exon 13	497bp	1324 C→T	ala433val	1/54
		1405 A→G	gln460arg	3/54
		1448 C→T	silent	2/54
		1494 A→G	ser490gly	2/54
		1513 A→C	glu496ala	8/54
		1628 G→T	silent	2/52
		1772 G→A	silent	24/54

Positions in the 5' UTR refer to SEQ ID NO: 1.

Positions in exons refer to SEQ ID NO: 2.

Positions in introns refer to SEQ ID NO: 3.

5 Positions in protein refer to SEQ ID NO: 4.

Example 2

Haplotype analysis

a) The following allele frequencies were determined in a Swedish population.

SEQ ID NO	Position	Frequency
1	1012	46/60
2	489	27/60
3	5579	39/60
2	835	16/58
2	853	3/60
2	1068	24/58
2	1096	6/58
2	1045	11/60
2	1513	10/60

10

b) Haplotype data.

Analysis of 15 Swedish families with at least one asthmatic child using primer extension (SNaPShot™, Perkin Elmer) genotyping and GeneHunter™ analysis demonstrated the following haplotypes:

15

	1012	489	5579	835	853	1068	1096	1405	1513	Frequency n/58
1	T	T	C	G	G	A	G	A	A	1
2	C	C	G	G	G	G	C	A	A	3
3	C	C	C	A	G	G	C	A	C	1
4	C	T	G	G	G	A	C	G	A	5
5	C	C	G	G	G	A	G	A	A	1
6	C	C	C	A	G	G	C	A	A	8
7	T	T	G	G	G	A	C	G	A	1
8	C	T	C	G	G	G	C	A	A	3
9	C	C	C	G	G	A	C	A	A	3
10	C	T	G	G	G	G	C	A	C	2
11	T	C	G	G	G	A	C	A	A	2
12	C	T	C	G	G	G	C	A	C	3
13	T	C	C	G	G	A	C	A	A	4
14	T	C	C	G	G	G	C	A	C	1
15	C	T	C	G	G	A	C	A	A	2
16	T	T	C	G	G	A	C	G	A	1
17	C	C	G	G	G	A	C	G	A	2
18	T	C	G	A	A	G	C	A	A	2
19	C	C	C	G	G	G	G	A	A	1
20	T	C	C	G	G	G	G	A	A	1
21	C	T	C	A	G	G	C	A	A	4
22	C	C	C	G	G	G	C	A	C	3
23	C	T	G	G	A	A	G	G	A	1
24	T	T	G	G	G	A	G	G	A	1
25	C	T	C	G	G	G	G	A	A	1
26	C	C	C	G	G	G	C	A	A	1

This results in the following proteins:

position	155	270	276	348	357	460	496	Frequency N/58
SEQ ID NO 4								
amino acid	Y	R	R	Y	S	Q	E	1
	Y	R	R	Y	T	R	E	7
	Y	R	R	Y	T	Q	E	2
	Y	R	R	Y	S	R	E	1
	Y	R	R	A	T	Q	A	5
	Y	R	R	A	T	Q	E	3
	Y	R	R	A	S	Q	E	1

	Y	R	H	Y	S	R	E	1
	Y	H	R	A	T	Q	E	4
	H	R	R	Y	T	Q	E	9
	H	R	R	Y	T	R	E	2
	H	R	R	A	T	Q	A	4
	H	R	R	A	S	Q	E	3
	H	R	R	A	T	Q	E	3
	H	R	R	Y	S	Q	E	1
	H	H	R	A	T	Q	A	1
	H	H	R	A	T	Q	E	8
	H	H	H	A	T	Q	E	2

c) Analysis

Transmission disequilibrium testing (TDT) of 15 Swedish families with at least one asthmatic child showed a significant excess of transmission of the A allele at position 1513 (giving Glu at position 496 of SEQ ID NO 4 protein) to offspring with asthma, $p=0.0125$.

- 5 Ben J. Gu, Weiyi Zhang, Rebecca A. Worthington, Ronald Sluyter, Phuong Dao-Ung, Steven Petrou, Julian A. Barden, and James S. Wiley, J. Biol. Chem. (2001) 276: 11135-11142 reported that Ala at 496 (C at 1513) leads to loss of function in P2X7. Only one polymorphism was reported since they only analysed the final exon for SNPs. Loss of P2X7 receptor function would possibly be protective against asthma and is compatible with our
- 10 TDT data.

Claims

- 1 A method for the diagnosis of a polymorphism in P2X₇ in a human, which method comprises determining the sequence of the human at one or more of the following positions: positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by
- 5 the position in SEQ ID NO: 1;
- positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and
- positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the
- 10 P2X₇ gene as defined by the position in SEQ ID NO: 3;
- positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;
- and determining the status of the human by reference to polymorphism in P2X₇.
- 2 Use of a diagnostic method as defined in claim 1 to assess the pharmacogenetics of a
- 15 drug acting at P2X₇.
- 3 A polynucleotide comprising at least 20 bases of the human P2X₇ gene and comprising an allelic variant selected from any one of the following:

Region	Variant SEQ ID NO: 1
5'UTR	936 A 1012 C 1147 G 1343 A 1476 G

Region	Variant SEQ ID NO: 2
exon 2	253 C
exon 5	488 A 489 T
exon 7	760 G
exon 8	835 A 853 A
exon 11	1068 A 1096 G
exon 12,	1315 G

exon 13	1324 T
	1405 G
	1448 T
	1494 G
	1513 C
	1628 T
	1772 A

Region	Variant
	SEQ ID NO: 3
intron E	4780 T
	4845 T
	4849 C
intron F	5021 C
	5554 (GTTT) _n , n=4
	5579 C
	5535 T
intron G	5845 T
	6911 C

- 4 A nucleotide primer which can detect a polymorphism as defined in claim 1.
- 5 An allele specific primer capable of detecting a P2X₇ gene polymorphism as defined in claim 1.
- 5 6 An allele-specific oligonucleotide probe capable of detecting a P2X₇ gene polymorphism as defined in claim 1.
- 7 Use of a P2X₇ gene polymorphism as defined in claim 1 as a genetic marker in a linkage study.
- 8 A method of treating a human in need of treatment with a drug acting at P2X₇ in
- 10 which the method comprises:
 - i) diagnosis of a polymorphism in P2X₇ in the human, which diagnosis preferably comprises determining the sequence at one or more of the following positions: positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1;
 - 15 positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and

- positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3; and
- positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;
- 5 and determining the status of the human by reference to polymorphism in P2X₇; and
- ii) administering an effective amount of the drug.
- 9 An allelic variant of human P2X₇ polypeptide comprising at least one of the following:
- a alanine at position 76 of SEQ ID NO 4;
- a tyrosine at position 155 of SEQ ID NO 4;
- 10 a glycine at position 245 of SEQ ID NO 4;
- a histidine at position 270 of SEQ ID NO 4;
- a histidine at position 276 of SEQ ID NO 4;
- a tyrosine at position 348 of SEQ ID NO 4;
- a serine at position 357 of SEQ ID NO 4;
- 15 a arginine at position 430 of SEQ ID NO 4;
- a valine at position 433 of SEQ ID NO 4;
- a arginine at position 460 of SEQ ID NO 4;
- a glycine at position 490 of SEQ ID NO 4; and
- a glutamic acid at position 496 of SEQ ID NO 4;
- 20 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic variant.
- 10 An antibody specific for an allelic variant of human P2X₇ polypeptide as defined in claim 9.
11. A polynucleotide comprising any one of the following twenty six P2X₇ haplotypes:

	1012	489	5579	835	853	1068	1096	1405	1513
	SEQ ID	SEQ ID	SEQ	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
	1	2	ID 3	2	2	2	2	2	2
1	T	T	C	G	G	A	G	A	A
2	C	C	G	G	G	G	C	A	A
3	C	C	C	A	G	G	C	A	C
4	C	T	G	G	G	A	C	G	A
5	C	C	G	G	G	A	G	A	A
6	C	C	C	A	G	G	C	A	A
7	T	T	G	G	G	A	C	G	A

8	C	T	C	G	G	G	C	A	A
9	C	C	C	G	G	A	C	A	A
10	C	T	G	G	G	G	C	A	C
11	T	C	G	G	G	A	C	A	A
12	C	T	C	G	G	G	C	A	C
13	T	C	C	G	G	A	C	A	A
14	T	C	C	G	G	G	C	A	C
15	C	T	C	G	G	A	C	A	A
16	T	T	C	G	G	A	C	G	A
17	C	C	G	G	G	A	C	G	A
18	T	C	G	A	A	G	C	A	A
19	C	C	C	G	G	G	G	A	A
20	T	C	C	G	G	G	G	A	A
21	C	T	C	A	G	G	C	A	A
22	C	C	C	G	G	G	C	A	C
23	C	T	G	G	A	A	G	G	A
24	T	T	G	G	G	A	G	G	A
25	C	T	C	G	G	G	G	A	A
26	C	C	C	G	G	G	C	A	A

12 A human P2X₇ polypeptide comprising one of the following eighteen combinations of allelic variant determined amino acids based on positions identified in SEQ ID NO: 4:

	155	270	276	348	357	460	496
1	Y	R	R	Y	S	Q	E
2	Y	R	R	Y	T	R	E
3	Y	R	R	Y	T	Q	E
4	Y	R	R	Y	S	R	E
5	Y	R	R	A	T	Q	A
6	Y	R	R	A	T	Q	E
7	Y	R	R	A	S	Q	E
8	Y	R	H	Y	S	R	E
9	Y	H	R	A	T	Q	E
10	H	R	R	Y	T	Q	E
11	H	R	R	Y	T	R	E
12	H	R	R	A	T	Q	A
13	H	R	R	A	S	Q	E
14	H	R	R	A	T	Q	E
15	H	R	R	Y	S	Q	E
16	H	H	R	A	T	Q	A
17	H	H	R	A	T	Q	E

18	H	H	H	A	T	Q	E
----	---	---	---	---	---	---	---

13 A polynucleotide which encodes any human P2X₇ polypeptide as defined in claim 12.

14 A method for the diagnosis of asthma or a predisposition thereto in a human, which method comprises determining the sequence of the human at one or more of the following positions:

- 5 position 1513 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and
position 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;
wherein presence of A at position 1513 or Glu at position 496 is diagnostic of asthma or a predisposition thereto.

ABSTRACT

TITLE:Chemical Compounds

5 This invention relates to polymorphisms in the human P2X₇ gene and corresponding
novel allelic polypeptides encoded thereby. The invention also relates to methods and
materials for analysing allelic variation in the P2X₇ gene, and to the use of P2X₇
polymorphism in treatment of diseases with P2X₇ drugs.

- 1 -
SEQUENCE LISTING

<110> AstraZeneca AB

5 <120> Chemical Compounds

<130> morten

<140>

10 <141>

<160> 4

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 4900

<212> DNA

<213> Homo sapiens

20

<400> 1

gactcactat agggagaccg gcagatctga tatcatcgcc actgtggatc cgaattctag 60
aaggcctatg ttctaagcat caggctttac ctgtgaatct cctcttttta cagatgaaga 120
tgactgtatc actcagattc ccggcaggaa agcaatggca tactcaagtg gggtaactaa 180
25 tgatggaacc atttaciaaag gtgtggacag agttaagaaa aagcaatagg agatagttag 240
cttcctgggg ctggtaagag tggggagccc ttaccactcc caggactaaa ggagggagtg 300
gtgcccagaa gccctgccta tatgcaactg agaagggcag ggccaggagg tcacgtccat 360
cctcactgct ctccagtctc ctgaactgga agccagaagg tgaggggaac cctgatgcag 420
tttgtatgtg tgagaaagta caattagttt agactgaaaa actgaaaatc taccgggcca 480
30 cttagcaggc tggaaataaca gaaatggatc aagccagctg taaagataac agggaacaat 540
aattctctgt agctgtaaag tgataatata accctgcata tttgagttag tgctgaaaca 600
ttgtccttta aaatcagaga ccttcagaaa ctctcgtgtt tgaattaca tgactaagac 660
tgaaatattc caattttgcc tgggaagattt aagtcattct gacacagaga agcagcctca 720
atttacaact caggagcaga gcttcagata aagattttct ggacacattt gacatgtatc 780
35 ttagctatgt tgcttcctag gaaacagggc cctgggtcct ctttgcaatc cagactgaag 840
ttgactgctt tgtacaaacc tgttttgctt tgagtccatc aaaacatgac ttcatttaga 900
ttttatctca actccacttt cctcggaatc ctatactaaa ttgctgtttt cctttgtttg 960
gtgatgtgcg tagctcttct ggtgggtggg gtcctcact gaataggcca ataaacctaa 1020
ctttgttggg ctgccactgt gtccttggtg atctttgggt gattgggtcta ggtcatagat 1080
40 cgacctgccg ggggtgcagag gagggtggag agtaactcag agggtaagc atgaaagatc 1140
tggcagaaaa ataaagcccc tccaccccca ccaccctac cctgcaaat ctgatttccc 1200
ccaccaactg cagaccagag tattataagg ggcggtggaa gaagaggggg agatcttcat 1260

ttacccagag ctccatataca tcaggggctg aataaagggt tgtagaaatg aatgaatcaa 1320
 tctctgagtg gggcttcagg cagtggaaag atctcagtc ttttctgagg cataatggaa 1380
 gctcccagtc ttgtgacatt tgcaaggctg cccctttctc ccaagagaca tgagaccaa 1440
 aaagtgaaag gaaagggggg aaaagggaga attctaaaaa tgccatcct ctgaacacca 1500
 5 tctttgtgta ggcattctggg ggaggccagc tgggtgagg tcatctgcca gccaggcccg 1560
 taggacttgg cgcttcttgt ttatcacagc cacatgtggg gccactgcca gggcccgccc 1620
 caactctgca gtcattggag gagcttgaag ttaaagactc ctgctaaaaa ccagtacgtt 1680
 tcattttgca gttactggga gggggcttgc tgtggccctg tcaggaagag tagagctctg 1740
 gtccagctcc ggcaggggag ggaggctgtc accatgccgg cctgctgcag ctgcagtgat 1800
 10 gttttccagt atgagacgaa caaagtcact cggatccaga gcatgaatta tggcaccatt 1860
 aagtggttct tccacgtgat catcttttcc tacgttttgg aagtgggagc tggggaggag 1920
 ccagatctct gcagtggccg acagcacaga aagccccagc gggcagcttc aggtgcacat 1980
 tctgaatctc acatggtttt cgaatctgag acgtgctctc acagccagct gggcgggagg 2040
 gaggaagcag cagcaggcaa gaggaacgg tgccaggctg cagcagagag aagccacagg 2100
 15 acaagcggga ttcctttctg ctctacttca ggcccggcag ggcgcgcaag gcaggcgctg 2160
 cctgggggag gtaggaaagc gcagggcaac accctggatc cccaggggagg aggcgaggat 2220
 ctcagggcac gcctggtgat catgctggca tctgagtcac catgcttggg aggaatagga 2280
 ccaggcttga aaatgtgtta taactttagg tctcaccaa cgtcagggaag gccctgcttt 2340
 ttgggtttttg tttcttctaa aagaaactta ctgagatata atttatacac catacaattg 2400
 20 acccatttaa aggttaccat ttaatgattt tcagattatt cccagagttg tgcaaccatc 2460
 cccacaatca attttagaat attttaatcg actcaaaagg aatcccacac tcttcacca 2520
 tcatttccaa cactgttctc cctccttccc acccatcaat ttcctttctg cctctatgga 2580
 ttgcccatt ctggacattt catataaatg gaatcacata atatgtggtc ctttgtggca 2640
 cttagcgtgt tttcaatgct catccatgtt gtagcatgtg ttgatacttc attcaatttt 2700
 25 tttttttaa gagacggggc ctactattt tgtccaggct ggtctcaaac tcttgactc 2760
 aagtgatctg cctgcctcgg cctcccaaag tgtcaggatt acaggcggtga gccattgcac 2820
 ccggtgata cttcattcct ttttacggct gagtagtact ccattgcatt gatagaccac 2880
 tttttctat ccattcatcc attgatggac attgggggtt tttctctttt ttggctatca 2940
 tgaataatgc cacatgaaca tttgtgtaca aggttttatg tggatatata ttctcctttc 3000
 30 tctcgaatat gtacctaaga gtaaaaattg ctaggtcata tgtaactat gtttcacctt 3060
 tggggggaat gtggagctga atttcacagc agctgcagtt ttttacatc ctatcagcag 3120
 agtatgaggg atccaatttc tccacatcct caccaacgct tgttatcgtc tgtctttttg 3180
 ggttttgtt ttgtcatttt gtttttgtct ttgagatgaa gtcttgctct gttgccagg 3240
 ctggagtgca gtggcgcaat cttggctcac tgcaacctcc acctccccgg ttcaagcgat 3300
 35 tctcctgct cagcctcatg agtagctggg attacagggt tgcgtcacca ctctcacta 3360
 atttttgtat ttttagtaga gatgaggttt cgccatgtag gccaggctgg tctcaaactc 3420
 ctgaacctca gtgatccgc cacttggtc tcccaaagtg ctgggattac aggcattgagc 3480
 cgccacgccc ggctgattgt ctgtcttttt tattatagcc atgctagtgg gtgtgaagtg 3540
 gtagttcatt gtgggtgtga tttgaatttc cctgatgggt agtgctctt attctctgtg 3600
 40 ctgattgata atgatgatga aggcaatttg tatctataga gtggcagtgt agtttactaa 3660
 gagttagggt aacttatttc atagtactgg ctatgtcttc tgggccaagt cattaacttc 3720
 tctgagcctc agtttctgca tctgttcata gggtgtggc aattaaccaa aaaaaaagg 3780

catgaacagc ccttatcatg atgactgaca taggataaga gctccataac tagtatctat 3840
 ttttaaaaat aatcttttta agtctgggag tgggtggctca cacctgtaat cccaacactt 3900
 tgggaggccg aggcgggttg atcacgaagt caggagtttg agaccagcct ggccaatatg 3960
 gtgaaacccc atctctacta aaaatacaaa aattagtggtg gagtgggtgt gcacacctgt 4020
 5 aatcccagct actaggaggg ctgaggcagg agaatcgctt gaaccgggag gcggaaggtg 4080
 cagtgaagcc agatcaagcc actgcactcc agcctgggtg acagagcaag actccatctc 4140
 aaaataataa taatagtaat aatttttttg attatataat agtatatatg tatataaaat 4200
 acatgtatgt atttttatct atatcctctg ctctgaccct caaagtaacc acgtccaagt 4260
 tcaggatttg aaatctggaa acgtggattc aaaaatcctt cacctctttg agccttggtt 4320
 10 tcatcatctg taaaatgggg agaattggtg ataggaatat taaatgaact aataaatgca 4380
 aagctgtttg agaaatatat ggcataatag aatccctgat taagtgttag ttcttattat 4440
 taataatgct attattagga ttattattat tcgattcata tgtttactgt tcaacaaata 4500
 ttgaatgata aacatatatg ctgggtcccg catggtggcc catgcctgta attccagcac 4560
 tttgggaggc caaggcgggc aggtcacttg aggtcaagag tttgagacca gcctggccaa 4620
 15 tgtggtggaa actccatctg tgctaaaaat acaaaaatta gccgggcatg gtggtgggtg 4680
 cctgtaatcc cagctactcg ggaggctgag acaggagaat cacttgaacc caggaggtgg 4740
 aggttgcagt gagccaagat tgcaccactg cactccagcc tgagccacag agcaagactc 4800
 tgtctcaaaa aaaaaaaaaa aaaatatata tatatatata tatatatata gtatttttag 4860
 tagagatggg gttttgccat ctcttatata tttttatatt 4900
 20

<210> 2

<211> 1853

<212> DNA

25 <213> Homo sapiens

<400> 2

aaaacgcagg gagggaggct gtcaccatgc cggcctgctg cagctgcagt gatgttttcc 60
 agtatgagac gaacaaagtc actcggatcc agagcatgaa ttatggcacc attaatgggt 120
 30 tcttcacagt gatcatcttt tctacgctt gctttgctct ggtgagtgac aagctgtacc 180
 agcggaaaga gcctgtcatc agttctgtgc acaccaaggt gaaggggata gcagaggtga 240
 aagaggagat cgtggagaat ggagtgaaga agttggtgca cagtgtcttt gacacccag 300
 actacacctt ccctttgcag gggaactctt tcttcgtgat gacaaacttt ctcaaaacag 360
 aaggccaaga gcagcgggtg tgtcccagat atcccaaccg caggacgctc tgttctctg 420
 35 accgaggttg taaaaagga tggatggacc cgcagagcaa aggaattcag accggaaggt 480
 gtgtagtgca tgaagggaac cagaagacct gtgaagtctc tgcctggtgc cccatcgagg 540
 cagtgaaga ggcaccccg cctgctctct tgaacagtgc cgaaaacttc actgtgctca 600
 tcaagaacaa tatcgacttc cccggccaca actacaccac gagaaacatc ctgccaggtt 660
 taaacatcac ttgtacctc cacaagactc agaattcaca gtgtccatt ttccgactag 720
 40 gagacatctt ccgagaaaca ggcgataatt tttcagatgt ggcaattcag ggcggaataa 780
 tgggcattga gatctactgg gactgcaacc tagaccgttg gttccatcac tgccgtccca 840
 aatacagttt ccgtcgctt gacgacaaga ccaccaacgt gtcctgtac cctggctaca 900

acttcagata cgccaagtac tacaaggaaa acaatgttga gaaacggact ctgataaaag 960
 tcttcgggat cggttttgac atcctgggtt ttggcaccgg aggaaaattt gacattatcc 1020
 agctgggtgt gtacatcggc tcaacctctt cctacttcgg tctggcggct gtgttcacgc 1080
 acttctcat cgacacttac tccagtaact getgtcgtc ccatatttat ccttgggtga 1140
 5 agtgcgtgca gccctgtgtg gtcaacgaat actactacag gaagaagtgc gagtccattg 1200
 tggagccaaa gccgacatta aagtatgtgt cctttgtgga tgaatccac attaggatgg 1260
 tgaaccagca gctactaggg agaagtctgc aagatgtcaa gggccaagaa gtcccaagac 1320
 ctgcatgga cttcacagat ttgtccaggc tgcctctggc cctccatgac acacccccga 1380
 ttcttgaca accagaggag atacagctgc ttagaaagga ggcgactcct agatccaggg 1440
 10 atagcccgt ctggtgccag tgtggaagct gcctccatc tcaactcct gagagccaca 1500
 ggtgcctgga ggagctgtgc tgcggaaaa agccgggggc ctgcatcacc acctcagagc 1560
 tgttcaggaa gctggtcctg tccagacagc tctgcagtt cctcctgtc taccaggagc 1620
 ccttgcctgc gctggatgtg gattccacca acagccggt gcggcactgt gctacaggt 1680
 gctacgccac ctggcgcttc ggctcccagg acatggctga ctttgccatc ctgcccagct 1740
 15 gctgcggctg gaggatccgg aaagagtctt cgaagagtga agggcagtag agtggttca 1800
 agagtctta ctgaagccag gcaccgtggc tcacgtctgt aatccacct ttt 1853

<210> 3

20 <211> 11266

<212> DNA

<213> Homo sapiens

<400> 3

25 catcacctac aaaggaaacc ccaaaccag tagcagtcac tcccattct ccccttcccc 60
 tgctcctggc cacagtctac tttctgtct tatagatgcc tattctggac atttctata 120
 aatagaattg tatatgggtg gcccttttgt gtctgtctt tttactcag catcatgttc 180
 tccaggtcca tccatgttgt agcctgtgtc attgcttcat ccttcttatg gctaaataag 240
 attctgtgta tgaatgtacc acattttatt tgctcattca tccgtcagtg gccacttgca 300
 30 tgggtttccac ttttttggcg attctgagta gtgtgtctat aagcattcgt gtgcacattc 360
 tgggtggatat cgaatcactt ctccacatct tagtaacaca cgtcacttac tccccactct 420
 gtcactcttc tatctgcagt atcccacccg caggacgctc tgctcctctg accgagggtg 480
 taaaaaggga tggatggacc cgcagagcaa aggtaccttc tgtttctttt cccgagaccc 540
 taggggtgga tggcttgga tcttggtgac atttgatgag cccaggtcag gtcttcagcc 600
 35 tctgctctca gctgccctct tccaccatca ccaagccata ggcgagtctg cccatgcttc 660
 ggctctgtcc ccagcagacc agctgctgac tgtaaacatg actccagttt tccagtgaga 720
 gaagaagctc ctaaaaacct agcaggttca ggattcta atcgtagaaaa ttcacatggc 780
 ctatagcatc atctgagtat tctaaacttt cccctgaat ttcctcaaag gttgaggacc 840
 atgaactttt acccccaggg gaacctggca gcaataccca tattaacctg cagaattttt 900
 40 tttgtttttt attttatttt attttttaa ctttttttgc actgttttat tttgattttg 960
 attttgattt tttttatat taagtgcagt gctattgcga tactgcagaa tttcttttate 1020
 tcacatttta acttaaaaag gcacagggca gcgagcgag aggtgtgtgc ctgtaatccc 1080

agcactttgg gaggggtgagg cagatggatg cttgaggtca ggggttcgag aacagcctgg 1140
 aaaacatggt gaaaccccg tctactaaa aatacaaaaa tcagccagac atggtggcac 1200
 acgcttataa tcccagctac ttgggaggct gagacgtgag aatcacttga acctggaagg 1260
 cagaggttgc agtgagccaa gatcatgcc ctgcactcca gcatgggtga cagagcgaga 1320
 5 ccccttttaa aaaaaaaaa aaaggcacag ggcaatttta aaaatactgc aaatagtaaa 1380
 aaaaaaaaa tcagtggta taatgcaaac acacacaaaa aggcataatgc ccattactgc 1440
 attctactcc atactgtatg tgtatttgag ttagtataaa agttatttta acattgctca 1500
 ctatttaatt aattctccct tggaaactga ttaatcatcc tggcactcca ggaagatgtg 1560
 ccatgctgat ttcattgctt tgcacatcct gggcaggctg tgtaccctt gagggacttg 1620
 10 tgcccccttg agaggccatg ttctagtcca ttataactaa gtgagagcat acacctgttc 1680
 cgctccccct atgggcacct tttcttataa agaaacaaaa gagccagcag aatccacagt 1740
 cttctctgtg tctctctgat ctttattatg tttgtctgt ttgccttgcc ttgtgttctg 1800
 tgtggttagg atgggcttga tggaaactga agctgcgtgg gttggaaagc ctggtcaaag 1860
 cctagtctct cgcccggtt gagttaatga tgcctcctt ggagaacgtc ctctctgcag 1920
 15 ttctttcaca tctgtggtt tacgatgctt tgaccctat aggaattcag accggaaggt 1980
 gtgtagtga tgaagggaac cagaagacct gtgaagtctc tgcctggtgc cccatcgagg 2040
 cagtgaaga gggcccccg tgagtcgat ggggagacag acacagtggc cctcagcggc 2100
 gaccagatga ggccttgccg aggtgcttg ggccttcccc tctcagcaca gccctgcaa 2160
 gtctgggtc ctaccggtt ggggacctt gcgtcttga tgcactgctt ggcacaaact 2220
 20 agtatctctg ggaggccat ggtggttgg aaactgttgt aacactcctg taccaactgg 2280
 taaatagcta ctacctgag catccttggg tgccttggc ccttctctc cccagatct 2340
 tccagggtac cccagacct cctcctgtag tgccacagca ggatccctt tgacttgctca 2400
 gtgtccatac tgagtgatca aggataggaa ggaaggagg agatggaaag gaaggacgaa 2460
 gcgaggaaag agaagggaag ggggaggaaa aagcaaaagg ggtgagggtta aaagaggggg 2520
 25 ggaaagggaag ttttctcaa ttaaatgctt acaatgacat acagatttg tggtcccttg 2580
 tattgatgct tgccttcaat acacaaagtc acaatgttaa atctcagaag ccacaagggc 2640
 tgatgtattt cagcagagaa tagttagaaa gacctggatt caattcctag ctctaacc 2700
 attttgctgt gtgtccttg gaaaatggct taacctctct gagtttcagt gtcctcacct 2760
 gtaaaagcag aataataatt tcaccaactt catagggctg ttgtaaggat taaatgagat 2820
 30 gatacttgta cagttattgt aaggtaagc ccatgcatgc ctggcttaca cacacacaca 2880
 cacacacaca cacacacag cacacacaca cacacacaca atctaccct agaagtgtgg 2940
 tggttctaga ccagcactgt ccaattgaac ttgatgcagt gatggaaatt tctgtatctg 3000
 tgctgtccaa tagggcagct actaggta tgtggctatt gactacatga aatgcgacta 3060
 ctgaattttt gaaagagatg atagatgata gatagaaaga tagatagata gataaataga 3120
 35 tagataatag atagatagac aggtagatag atagatagat agatagatag atagatagat 3180
 agatagagtt ttgctatgtt gccaggctg gttttgaact cctgggctca agcagctctc 3240
 ctgccttggc ctcccaaagt gctgggggtta caggtttgag ccattgctcc cagcctgaat 3300
 ttttaattaa atttaattt aaatagccac acatgtctag tggctaccat attggacagc 3360
 gcagttctag accgatgtga ttcaggatca ttccctcagc atcgtggggc aaagagaaaa 3420
 40 ctgccccaa ctggcctgta gaaggctcag ggaagggtt cccaatgccg ggatgggggg 3480
 tgcgctcagc agcatcacc cttatgatc tcaatcgcta atagctccac tcaggttcat 3540
 ttctcggkca ggggcatttc tttgggaatc accagctct gggagatata gcagcctcca 3600

ctcaggtagt ccttggtcaa gacaagcggc ccttgactga ctgcagtttc agttccagct 3660
ctgctatcaa ctactcatt aaataaactg catctccagt gtgcctgcct ctgggctgga 3720
ttttgacgtg acctgggcaa gcaactccct gaacttcagt ttctcatata ttatatgaat 3780
tagctaagat gggttcgtta atcattcatt caacacatcc atcaccacgt agtaggtgtt 3840
5 agatatttat ttcatacgt actacgcata agagactttg ctaagtttta ggtaaaatac 3900
aagtcaccaga tacggagcaa gtctcaacca ctgtacatac ctgaatgtgt aattacatca 3960
ctgtaagagg tgccacagta aatgccactg ggtcttgtgt tagtccattc tcacacaaaag 4020
aactacctag ccagggtgcg tggtctacgc ctgtaatccc aacacttttg caggctgagg 4080
caggcggatc acttgaggtc aggagtttga taccagcctg gcaaacatgg tgaaacccca 4140
10 tctctattaa aaaatgcata aattagccag gtgtggtggc acacgcctgt aatcctggct 4200
actcgggagg ctgaggcagg agagtcgctt gaaccgggga gatggagggt gcagtgaccc 4260
gagatcgcgc cactgcactc cagcctgggt gacagagtga gactccatct cagaaaaaaa 4320
taaaaaataa aataaagaac tacctgagac caaacacttt acgaaaaaaa agaggtttaa 4380
ttgactcaca gctccacagg cttaacagga agcctcagga gacttacaat catggcagaa 4440
15 gggaaggagg aagcaaacac atcttaccat gatggagcag gaggcgggtt tcgggggatg 4500
tgccgcacac ttttaaatga tcagatctcg tgagaactca ctactatca cgagaacagc 4560
aaggaggaaag tccgccccca tgattcagtc acctcccacc agggccctcc tctggcacat 4620
ggggattaca attcaagatg agatttgggt ggggacacag agccaaacca tatcagatct 4680
caagaaggga gaaattcttc ttggaggagc tggagggggt ttgtggagag tttcagaatg 4740
20 ctttgcaccac taggtttgct gtatccattt ctcttcatgc atcccaaaga ccaagccaag 4800
aaaccagaag cctctggtcc cactggccca tgggtccctc cggtcccccac cgtcactaat 4860
ggccattttg catgtctctc tcccaggcct gctctcttga acagtgccga aaacttact 4920
gtgctcatca agaacaatat cgacttcccc ggccacaact acaccacgta agtgcccagg 4980
ctgcctggct gtcttagtta tctactgctg agtaataaat tatcccaaac ctcaagaagc 5040
25 tgaaacaaca aacgcctatt gtctcccacg gtttctgttg gtcaggaatc tgggaatgac 5100
tttgcctcgt gggtctggct caaggctctg caggttgtag ccaagctgtc aaccagggtc 5160
gcagtcattt ctaggcttga ctggggcttg agaacccttt tccaagctct cacacagttg 5220
ctcgtgggag agctcagttc ctaccacgt gaacctcgcc ctagaccact tgagtatcct 5280
tggtatatgg tggctggctt ctcccagagc aagtgaacca agagagacag agcaagcaac 5340
30 caagagtata accaagatgg aagccacagt ctttgggggg agaccccaac acttctgcca 5400
tatgccattg gtcacacaga tcaaccctgg tccagtgtga gaggccactg cccaggggtc 5460
ccaggaggca gggatcattt ggggctttca tggaaacctc ccaccacact ggctcactcc 5520
tggaagagag acagatctgt tttcaatcga gatgtttgtt tgtttgcttt taattatgga 5580
caggagaaac atcctgccag gtttaaact cacttgtaac ttccacaaga ctcaaatcc 5640
35 acagtgtccc attttccgac taggagacat cttccgagaa acaggcgata attttccaga 5700
tgtggcaatt caggttggtg gtgctttgta cactgggatg tggggctgtg tgtctaggga 5760
tggaaggatg caaacagcca agaggccggg ccaactgggtc ttcataatgt ggctcacatt 5820
tactgagcat ttagtaaatc caccgctgc gctaaggctt ttacctacgc tacctcgtca 5880
aatcccaaaa caatccttat gagtgaagc tacttggtgt attcctttcc tgtggctgct 5940
40 gtagcaagtt atcaaagctt agtggcttca aacaacacat atttgcttat gttgccagag 6000
atcagaagtt ggagatgatt ttccctgagc cagggcgggt ctcctctggt gactttaagg 6060
gagaatccag ttctcagct tttccactt ctggagctgc attccttgca tttcttcaaa 6120

gccagcagca taacatcttg cctcagtgcc cactttcact ccctatcctg tgtccaatct 6180
 ccctttgcct ctgtcttaaa aagagagaga gcatttacia gagggggcat ttaaggacca 6240
 actggataat ccaggataat ctcccactc aagatccttc atttaggctg ggcacgggtg 6300
 ctcagtcctg taatcccagc actttgggag gctgaggtg gtggatcacc tgaggctcagg 6360
 5 agttcaacac cagcctggcc aacatggtga aagcccatct ttactaaaaa tacaaaaaaa 6420
 aaaaaaaaat agccgggcat gattgcgggc tctgttaatc ccagctactc gggaggctga 6480
 gacaggagaa tcgcttgaac ctgggaggca gaggttgag tgagccgaga tcgcaccact 6540
 gcactccagc ctaggtgaca agagcgaaac tccatctcaa aaaaaaaaaa aaatccttc 6600
 atgtattcgc atctgcaaag agctttccct aggggagtag taggaggtaa agcagaaaag 6660
 10 atatttgata gaggccctg aattccagtc taataagttt ggacttgatc tttaatggg 6720
 gcgtgggggg cattaaaggt gtttgggtac aggagtggc tgttgaaagt tgtatttttag 6780
 gacaatgagt ttaacagtga tgtgtcccag acgggggtag ggagagtga gagatgcgat 6840
 tgtggctgcc acaataacac ttgtgcgagt taggtggggc tgtacatatg gttcttcaat 6900
 cagcattttt tctctaaaaa ccttaagcaa tccctggctat gcaggagat gtctggcgg 6960
 15 tgcgtaactc acaccagca gccatagaga ctgtccctg ttgatccttc agggcggaat 7020
 aatgggcatt gagatctact gggactgcaa cctagaccgt tggttccatc actgccgtcc 7080
 caaatacagt ttccgtgcc ttgacgaca gaccaccaac gtgtccttgt accctggcta 7140
 caacttcagg taactccaag gccagggtca aactcacca gtggctgaat cgcattccca 7200
 ggaactgggt agactaattt tggtttccaa ggcaacaaga tgaatgaaa aagactttct 7260
 20 ctaagaacta ggtgataact gaattttttc cataattttt taaaattctc aaaagagata 7320
 cactctttat tttttactta ttttttttt tttgaaatgg agtctcactc tgtcaccag 7380
 gctgaagtgc agtggcgcca tctcagtcac tgcaaaactc cgcctcccag gttcaagcga 7440
 ctctcctgcc tcagcctccc aagtagctga gattacaggc ggatgcacac tgtttataaa 7500
 acaaaactat tgggaaacag aaaagcatag agggggatca aaatcgcca taattcccct 7560
 25 accctgaaat aatcaataac aaccctcggg ggaattttcc tcatctgtac caattatttc 7620
 atacagctcc tatgagatca tagcatatat atatatatat cttgtggtat tctgcagggt 7680
 ttttcatacc acagccactc aaaattcttt gtaaccatca cattaatgat cataacattc 7740
 cattttgtag gtgaacaaat aacaactgct acaattcagg aagtgttttc ttttcttttc 7800
 ttttcttttc ttttttttt ttagatggag tcacactctg cttgcccagg ctggagtga 7860
 30 gtggcatgat ctcagctcac tgcaacctct gcctcctagg tccaagcgat cctccacct 7920
 cccaagtctc tgggaccaca ggcagtgtgc accacacca gctaattttt gtatattcag 7980
 tagagatggg gtttcactgt gttggccagt ctggtctoga actcttgacc tcaagtgatc 8040
 tcccacctt ggcttcccaa agtgctagga ttacagtcac gagccactgt gcctggcca 8100
 aggagggttt tccatatacc aagcactccc catcgccatc cctaaatctc ccaacaacc 8160
 35 tggaaggaag atattgtttc tggaagatga tttgccaag acccagct gatagtacat 8220
 gtttgcataa ttctaacca cgttactct gacccacac tcacactccc atcccttccc 8280
 tcccactctc aatgattttc tcaccgtacg cctccatgaa ttgaatattt gagggtgttc 8340
 ccagtttttc tagtacaagt aaccacagtg tgcactttg caccgtaaac ttcttctttg 8400
 aattccaggg ttacttccct aggataaatt tcttagactt attgaatcaa aggttgtgaa 8460
 40 cattttatca tatgttttt atttttaaaa atatctatgg ttataatgtt tcattttttt 8520
 ttctgagaca gagtctcact ctgtcaccca ggttgagggtg gaccgggtgc aattatagct 8580
 cactgcaacc tctgcctccc aggcccaagt gatcctccca cctcagcctc ctgagtagct 8640

aggactacag gtgcatgccca ccatgccccag ctaatttttta aaattttttt gtagagtogg 6700
ggctctacta tattgccccag gctgggtctca aactcctggc tcaagcaatc cgctgcctt 8760
ggcctcctaa agcgttggga ttgcaggtgt gagctactgc acctggccta taattttcat 8820
ttctaggatt tttatttggg gctttttcaa agtcatctat tattgttcca gtgagtccca 8880
5 ttcttacctt aaggatccta ctcttctgt ccattctact gtatcattcc tttcataccg 8940
acctattatc tgaagtaact tgggtgggag ttctcctcgt gggctttgaa atactgtctt 9000
cagtagaaaa gatcttatgc aaagtcttgc atgtgctgtg tgttatggag tattccttat 9060
atattactca aagcagcttc atgaactggc aggcagcccc ttaaagtgtt ttctgtttct 9120
gtttttttgt tttttgggtt gcatgatgtt ttaaaacttg agacaggcca ggtgcggtgg 9180
10 cttatgcctg taatcccagc actttgggag gccaaagggtg gaggatcact tgaacccggg 9240
ggtttgaggc tagcctgggc aacataggga gaccccatct ctacaaataa taatttttaa 9300
aacatcagcc aggtgtgggg gcatgcacct ctgggtcccag ctactcagga ggctgaggca 9360
ggaggattgc ttgaacctgg gaggttgagg ctgcagtga cctgtgttgt gccactgcac 9420
tccagcctgg gtgacagagt gagaccctta catgggtggc actggctgga gctgagtatc 9480
15 agtggtocta tttagaaagg ggctgggctt tctggttcat cactgtcccc gccgtcctt 9540
agtgcctata cctggcccac atcactcatt tctgtcatct gcctggcccc tgtgtagaca 9600
tttgagtttg aaaccttga ctcaaaggca ggctgatgct ttttgcttcc tctggatcaa 9660
tggaatttca tccaaggcaa tggaaccagc tcttaattgt gataactttt tgatcatccc 9720
ctgccactgt gctgaatagg cttatggcca ttaagaagag aggacaggat gaatggctcc 9780
20 ctgactgact gcccttccag ggtgtttttt tagctgtcag cagaagcatg cggggcagtg 9840
taccaatcag gtgtcagcaa gtgtccttcc agcgactgag ttgagcaca aaacatctgc 9900
tcttgagag acctgagccc tctgaaggcc tcagccagtt atgatgttaa tgttctttta 9960
gaacaaagtg gtacacccat ttgttgtctg gaatgagcac cagaacaaat ctttggccaa 10020
aaataaattg ttgagggccg ggagcagtg cttatgcctg taatcccaac actttgggag 10080
25 gccgaagcag gaggatcacc tgaggtcagg agttcagac cagcctggcc aacatggtga 10140
aacctgtct ctctaaaaa taaaaaatt agctggacgt ggtgacaggt gcctgtaata 10200
cagctactgg gaggtgagg cagggagaac tgcttgaacc cggaagggtg aggttgcagt 10260
gagccggggt catgccactt cactccagcc tgggcaacag agcaaagctc tgtctttaaa 10320
aacaacttaa ataaataaat aaattgttga ggtctgatga gtaagtggac aagttatttt 10380
30 ccagcagaca cacaaaagag aaggaaatta cagggtatag gaggtatttc agaaaatata 10440
actttctaaa acataggaag ttgaagaagt tgatcacatt acagaattct gttgtttaga 10500
aaatgacctg tggcgaaatg tcttattca gtgaatagg gattccgctt atgcacgacc 10560
tgtgtgaagt ggatcaggcc acccagaatg cacgatgcgc ttctcaggcc cagcaggagt 10620
atgtgtctgt gtaatttcc tgtggctatt atgactaatt gccacaaatg tggtggtta 10680
35 aaacaacaga aattaatctt cttatagttc tggaaaccag aagtttggaa tcaagatgtc 10740
agcagggcca cactcgtct gatgctctac gggagggtcc tctcttgcct cttccagcgt 10800
ctggtggtc caggcattcc ataactttat agcagcgtcc cacaaatctc tgccctccatc 10860
ctcacatggc cttctccact gtgtctctat gtcttcaatc tctttttttt tttttttttt 10920
ttgaggcagg gtttccactc agtctcctag actgaagtgc aatggcgtaa tttcgggtca 10980
40 ctgcaacctc tgctcccgg gctcaagcga tttgatctct cctttatctt ataaagatac 11040
tagtcattgg atttggggct taccctaaat ccaggataat ctcatcttga gatgtttaac 11100
ttaattatat ctgcaaacac tgtatttcca aataagggtca tatcacagcc actagggatt 11160

100203 GB-2

- 9 -

agatacttga acatatctta tttgggggct caacccattc cagtgtacga aaaacactct 11220
tggtcaaggc ccgatgtttc tcagggcata gcccaactgac tacctg 11266

5 <210> 4
<211> 595
<212> PRT
<213> Homo sapiens

10 <400> 4
Met Pro Ala Cys Cys Ser Cys Ser Asp Val Phe Gln Tyr Glu Thr Asn
1 5 10 15

Lys Val Thr Arg Ile Gln Ser Met Asn Tyr Gly Thr Ile Lys Trp Phe
15 20 25 30

Phe His Val Ile Ile Phe Ser Tyr Val Cys Phe Ala Leu Val Ser Asp
35 40 45

20 Lys Leu Tyr Gln Arg Lys Glu Pro Val Ile Ser Ser Val His Thr Lys
50 55 60

Val Lys Gly Ile Ala Glu Val Lys Glu Glu Ile Val Glu Asn Gly Val
65 70 75 80

25 Lys Lys Leu Val His Ser Val Phe Asp Thr Ala Asp Tyr Thr Phe Pro
85 90 95

Leu Gln Gly Asn Ser Phe Phe Val Met Thr Asn Phe Leu Lys Thr Glu
30 100 105 110

Gly Gln Glu Gln Arg Leu Cys Pro Glu Tyr Pro Thr Arg Arg Thr Leu
115 120 125

35 Cys Ser Ser Asp Arg Gly Cys Lys Lys Gly Trp Met Asp Pro Gln Ser
130 135 140

Lys Gly Ile Gln Thr Gly Arg Cys Val Val His Glu Gly Asn Gln Lys
145 150 155 160

40 Thr Cys Glu Val Ser Ala Trp Cys Pro Ile Glu Ala Val Glu Glu Ala
165 170 175

Pro Arg Pro Ala Leu Leu Asn Ser Ala Glu Asn Phe Thr Val Leu Ile
 180 185 190

5 Lys Asn Asn Ile Asp Phe Pro Gly His Asn Tyr Thr Thr Arg Asn Ile
 195 200 205

Leu Pro Gly Leu Asn Ile Thr Cys Thr Phe His Lys Thr Gln Asn Pro
 210 215 220

10 Gln Cys Pro Ile Phe Arg Leu Gly Asp Ile Phe Arg Glu Thr Gly Asp
 225 230 235 240

Asn Phe Ser Asp Val Ala Ile Gln Gly Gly Ile Met Gly Ile Glu Ile
 15 245 250 255

Tyr Trp Asp Cys Asn Leu Asp Arg Trp Phe His His Cys Arg Pro Lys
 260 265 270

20 Tyr Ser Phe Arg Arg Leu Asp Asp Lys Thr Thr Asn Val Ser Leu Tyr
 275 280 285

Pro Gly Tyr Asn Phe Arg Tyr Ala Lys Tyr Tyr Lys Glu Asn Asn Val
 290 295 300

25 Glu Lys Arg Thr Leu Ile Lys Val Phe Gly Ile Arg Phe Asp Ile Leu
 305 310 315 320

Val Phe Gly Thr Gly Gly Lys Phe Asp Ile Ile Gln Leu Val Val Tyr
 30 325 330 335

Ile Gly Ser Thr Leu Ser Tyr Phe Gly Leu Ala Ala Val Phe Ile Asp
 340 345 350

35 Phe Leu Ile Asp Thr Tyr Ser Ser Asn Cys Cys Arg Ser His Ile Tyr
 355 360 365

Pro Trp Cys Lys Cys Cys Gln Pro Cys Val Val Asn Glu Tyr Tyr Tyr
 370 375 380

40 Arg Lys Lys Cys Glu Ser Ile Val Glu Pro Lys Pro Thr Leu Lys Tyr
 385 390 395 400



Val Ser Phe Val Asp Glu Ser His Ile Arg Met Val Asn Gln Gln Leu
 405 410 415

5 Leu Gly Arg Ser Leu Gln Asp Val Lys Gly Gln Glu Val Pro Arg Pro
 420 425 430

Ala Met Asp Phe Thr Asp Leu Ser Arg Leu Pro Leu Ala Leu His Asp
 435 440 445

10 Thr Pro Pro Ile Pro Gly Gln Pro Glu Glu Ile Gln Leu Leu Arg Lys
 450 455 460

15 Glu Ala Thr Pro Arg Ser Arg Asp Ser Pro Val Trp Cys Gln Cys Gly
 465 470 475 480

Ser Cys Leu Pro Ser Gln Leu Pro Glu Ser His Arg Cys Leu Glu Glu
 485 490 495

20 Leu Cys Cys Arg Lys Lys Pro Gly Ala Cys Ile Thr Thr Ser Glu Leu
 500 505 510

Phe Arg Lys Leu Val Leu Ser Arg His Val Leu Gln Phe Leu Leu Leu
 515 520 525

25 Tyr Gln Glu Pro Leu Leu Ala Leu Asp Val Asp Ser Thr Asn Ser Arg
 530 535 540

30 Leu Arg His Cys Ala Tyr Arg Cys Tyr Ala Thr Trp Arg Phe Gly Ser
 545 550 555 560

Gln Asp Met Ala Asp Phe Ala Ile Leu Pro Ser Cys Cys Arg Trp Arg
 565 570 575

35 Ile Arg Lys Glu Phe Pro Lys Ser Glu Gly Gln Tyr Ser Gly Phe Lys
 580 585 590

Ser Pro Tyr
 595

40

Application No: _____

Pillsbury ~~Waltham~~

Inventor: J. E. N. MORTEN

Date: 10/16/01

Original #: ASTRAZENECA (100203/US)

CL.# 9901 M# 283779